Ultrasound

Cardio-oncology

Managing cardiotoxicity risks at every step

Because cancer patients have on average a 2-6 times higher cardiovascular disease mortality risk than the general population¹, prompt, reliable identification of at-risk patients is crucial. And once treatment is underway, close monitoring could help cardiologists detect potential biomarkers that may indicate the early stages of cardiac toxicity.

The European Society of Cardiology (ESC) Guidelines for Cardio-oncology² reflect the priorities for the prevention and monitoring of cardiotoxicity risks.

Overview

Overview

Solutions in line with ESC Guidelines on cardio-oncology

We are ready to support you and your patients every step of the way along their cancer treatment journey. Our AI-based ultrasound solutions support a comprehensive baseline assessment and reduce variability between users. Powerful workflow solutions provide multidisciplinary cardio-oncology teams with a patient-centric overview.
Benefits
Benefits
Benefits

Access patient data, including ECG, blood pressure, biomarker data and high-quality images, in a longitudinal patient-centric view.

Define robust baseline risk predictors for cardiotoxicity by performing risk stratification assessments using a highly standardized, easy-to-follow approach.

Capture superb images and robust quantification for accurate and consistent measurements that inform and guide the patient journey.

In less than three minutes, gather the necessary data to inform stratification and treatment frequency decisions.³
Key features
Key features
Features

AutoStrain provides automated, robust and reproducible global longitudinal (GLS) strain measurement with a single button push.

Dynamic HeartModel* measures 3D ejection fraction (3DEF) in seconds as part of a routine workflow, harnessing AI for enhanced cardiac function assessments.

iRotate keeps the transducer in a fixed position, facilitating reproducible images and helping bridge the gap between 2D and 3D thinking.

Fast-SENC and MyoStrain** combine to detect early dysfunction of the heart across 48 segments with a 12-heartbeat MRI scan**, helping clinicians in preventing and managing heart failure.

Featured products for Managing Cardiotoxicity

EPIQ CVx

EPIQ CVx features exceptional imaging, high exam efficiency and robust, reliable quantification capabilities. You can quickly and easily acquire high-quality, standard 2D imaging, complemented by AI-driven 3D imaging, for a consistently strong baseline assessment.

^{Affiniti CVx}

Affiniti CVx delivers outstanding imaging to meet the demands of cardio-oncology imaging. Advanced clinical capabilities and automation tools to help you deliver better care to more patients.

Ultrasound Workspace

Ultrasound Workspace is a holistic, scalable cardiovascular viewing, analysis and reporting system. It provides high levels of AI-powered automation to increase reproducibility and enhance diagnostic confidence to manage and support cardio-oncology patients.

Cardiovascular Workspace

Cardiovascular Workspace*** image and information management provides one spot for patient information, including ECG, blood pressure, biomarker data and images. Information is presented in a longitudinal, patient-centric view that can be accessed from nearly anywhere to support a multidisciplinary team.

Advanced Visualization Workspace

Advanced Visualization Workspace 15 is a comprehensive, scalable image post-processing platform, seamlessly integrated within your enterprise, helping physicians perform advanced analysis even in complex settings.

^{Ingenia Ambition 1.5T X}

The Ingenia Ambition 1.5T X delivers high quality images, reliable performance and patient-centered productivity. Its fully sealed magnet with only seven liters of liquid helium (instead of the usual 1,500 liters) is a safeguard against the consequences of helium scarcity and enables easy siting.

“Dynamic HeartModel and AutoStrain provide valuable insights to support cardiovascular monitoring and cardiotoxicity prevention, in close collaboration with oncologists and hematologists.”

Dr. Teresa López Fernández

Cardiac Imaging and Cardio-Oncology Unit Leader

La Paz University Hospital

Madrid, Spain
“Sometimes, our patients must move quickly between the cardio-oncology unit, echo lab and outpatient clinic. We need to access reports very quickly – maybe within an hour – so that’s why the cardio-oncology workflow needs to be perfect.”

Dr. Jorge Solis

Director of Non-Invasive Cardiology and Valvular Heart Disease Unit

Hospital Universitario 12 Octubre

Madrid, Spain
“Collaboration today is crucial. You need to speak the same language – which is why it is so important to have a system in which you have all the data of your patients – for EKG, to echo, to cardiac CT.”

Dr. Valentina Volpato

Head of Cardiac Imaging Department

Nuovo Galeazzi Hospital

Milan, Italy

Documentation

Resources: Using advanced ultrasound tools to assess CTRCD (cancer therapy-related cardiac dysfunction (9.7MB)

AutoStrain LV

Revealing new insights
Clinical articles: Automated transthoracic three-dimensional echocardiographic quantification of the left heart chambers

Rapidly identifying asymptomatic patients at risk of heart failure

Guidelines for Patients: What patients need to know

Technologies and innovations

Ultrasound AI Solutions

Philips AI-based ultrasound solutions integrate into everyday clinical workflows and are designed to make it easier and faster for clinicians to acquire, select, measure and report accurate results.

Footnotes

*HeartModel, previously sold under the name HeartModel A.I., is an advanced automation solution, not currently certified as artificial intelligence.

***Philips Cardiovascular Workspace is the commercial name of the medical device Philips IntelliSpace Cardiovascular.

[1] www.escardio.org/The-ESC/Press-Oﬃce/Press-releases/Cancer-patients-are-at-higher-risk-of-dying-from-heart-disease-and-stroke

[2] Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., Cutter, D. J., De Azambuja, E., De Boer, R. A., Dent, S. F., Farmakis, D., Gevaert, S. A., Gorog, D. A., Herrmann, J., Lenihan, D. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal, 43(41), 4229–4361. https://doi.org/10.1093/eurheartj/ehac244.

[3] López-Fernández, T.MD Cardiac Imaging Laboratory, Cardio-oncology unit, Hospital La Paz Institute for Health Research, Madrid, Spain, “Using advanced ultrasound tools to assess CTRCD (cancer therapy-related cardiac dysfunction), 2020.

[4] Bringing 3D ultrasound into practice for cardiac quantification, Philips, 2018. https://www.philips.com.au/healthcare/white-paper/3d-ultrasound-for-cardiac-quantification

Cardio-oncology

Managing cardiotoxicity risks at every step

Solutions in line with ESC Guidelines on cardio-oncology

Benefits

Features